Phase I/II Study of SRP-4053 in DMD Patients

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

This is a first-in-human, multiple-dose 2-part study to assess the safety, tolerability, efficacy, and pharmacokinetics of SRP-4053 in Duchenne muscular dystrophy (DMD) patients with deletions amenable to exon 53 skipping.

Condition or disease	Intervention/treatment	Phase
Duchenne Muscular Dystrophy	Drug: Placebo; Drug: SRP-4053	Phase 1; Phase 2

Detailed Description:

Part 1: Randomized, placebo-controlled dose-titration to assess safety, tolerability and pharmacokinetics of 4 dose levels of SRP-4053 in genotypically-confirmed DMD patients with deletions amenable to exon 53 skipping.

Part 2: Open-label evaluation of SRP-4053 in patients from Part 1, along with newly enrolled DMD patients with deletions amenable to exon 53 skipping and an untreated group of DMD patients with deletions not amenable to exon 53 skipping.

Safety, including adverse event monitoring and routine laboratory assessments, will be followed on an ongoing basis for all patients.

Clinical efficacy, including functional tests such as the six-minute walk test (6MWT), will be assessed at regularly scheduled study visits. Patients in the treated groups will undergo one baseline and one follow-up muscle biopsy. Patients in the untreated group will not undergo biopsies and will follow an abbreviated schedule of study assessments.

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	39 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:	Masking Description: Part 1 is double-blind and randomized; Part 2 is open-label.
Primary Purpose:	Treatment
Official Title:	A 2-Part, Randomized, Double-Blind, Placebo-Controlled, Dose-Titration, Safety, Tolerability, and Pharmacokinetics Study (Part 1) Followed by an Open-Label Efficacy and Safety Evaluation (Part 2) of SRP-4053 in Patients With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
Study Start Date :	December 2014
Estimated Primary Completion Date :	March 2019
Estimated Study Completion Date :	June 2019

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Experimental: Part 1: SRP-4053; Patients will receive SRP-4053 intravenous (IV) infusions, weekly, at escalating dose levels as follows: Weeks 1-2, 4 mg/kg/week; Weeks 3-4, 10 mg/kg/week; Weeks 5-6, 20 mg/kg/week; Weeks 7-12, 30 mg/kg/week. Dosing will be interrupted or halted if specific predefined stopping criteria are met or if warranted at the discretion of the Sponsor or Investigator.	Drug: SRP-4053; SRP-4053 solution for IV infusion
Placebo Comparator: Part 1: Placebo; Patients will receive SRP-4053 placebo-matching IV infusions, weekly, for 12 weeks. Dosing will be interrupted or halted if specific predefined stopping criteria are met or if warranted at the discretion of the Sponsor or Investigator.	Drug: Placebo; SRP-4053 placebo-matching solution for IV infusion
Experimental: Part 2: SRP-4053; All eligible patients from Part 1, as well as new patients, will receive SRP-4053 30 mg/kg/week IV infusions, weekly, for up to 168 weeks.	Drug: SRP-4053; SRP-4053 solution for IV infusion
No Intervention: Part 2: Untreated Group; Patients with DMD who have a genotypically confirmed deletion of exon(s) not amenable to treatment by exon 53 skipping, but who otherwise meet the same eligibility criteria as treated patients newly recruited to Part 2, will undergo the same study assessments as treated Patients (except for pharmacokinetic [PK] sampling and muscle biopsies), but at a reduced schedule through Week 144.

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Part 1: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: approximately 12 weeks ]
2. Part 2: Change From Baseline in the Total Distance Walked During 6-Minute Walk Test (6MWT) at Week 144 [ Time Frame: Baseline and Week 144 ]
3. Part 2: Change from Baseline in Dystrophin Protein Levels Determined by Western Blot at Week 48 [ Time Frame: Baseline to Week 48 ]

Secondary Outcome Measures :

1. Part 1: Maximum Plasma Concentration (Cmax) [ Time Frame: Pre-dose, 5 to 10 minutes and 1 to 24 hours post-dose at Weeks 1, 3, 5 and 7 ]
2. Part 1: Time to Maximum Plasma Concentration (Tmax) [ Time Frame: Pre-dose, 5 to 10 minutes and 1 to 24 hours post-dose at Weeks 1, 3, 5 and 7 ]
3. Part 1: Area Under the Plasma Concentration-time Curve (AUC) [ Time Frame: Pre-dose, 5 to 10 minutes and 1 to 24 hours post-dose at Weeks 1, 3, 5 and 7 ]
4. Part 1: Apparent Volume of Distribution at Steady State (Vss) [ Time Frame: Pre-dose, 5 to 10 minutes and 1 to 24 hours post-dose at Weeks 1, 3, 5 and 7 ]
5. Part 1: Elimination Half-life (t½) [ Time Frame: Pre-dose, 5 to 10 minutes and 1 to 24 hours post-dose at Weeks 1, 3, 5 and 7 ]
6. Part 1: Total Clearance (CL) [ Time Frame: Pre-dose, 5 to 10 minutes and 1 to 24 hours post-dose at Weeks 1, 3, 5 and 7 ]
7. Part 1: Mean Residence Time (MRT) [ Time Frame: Pre-dose, 5 to 10 minutes and 1 to 24 hours post-dose at Weeks 1, 3, 5 and 7 ]
8. Part 1: Urinary Clearance (CLR) [ Time Frame: Day 1, 0-4 hours, 4-8 hours, 8-12 hours, and 12-24 after initiation of dosing ]
9. Part 2: Change from Baseline in Forced Vital Capacity Percent Predicted (FVC%p) through Week144 [ Time Frame: Baseline through Week 144 ]
   The FVC is the maximal volume of air that can be exhaled from full inhalation by exhaling as forcefully and rapidly as possible. Patients will be assessed with delayed in the loss of respiratory function.
10. Part 2: Change from Baseline in Dystrophin Intensity Levels Determined by Immunohistochemistry (IHC) at Week 48 [ Time Frame: Baseline and Week 48 ]
11. Part 2: Exon 53 Skipping Determined by Measurement and Sequence Verification of Exon 53 Skipped Messenger Ribonucleic Acid (RNA) [ Time Frame: Baseline and Week 48 ]

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	6 Years to 15 Years (Child)
Sexes Eligible for Study:	Male
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

• Diagnosed with DMD, genotypically confirmed.
• Intact right and left biceps muscles or an alternative upper arm muscle group.
• Stable pulmonary and cardiac function.
• Minimum performance on 6MWT, North Star Ambulatory Assessment, and rise (Gowers) test as specified in the study protocol.
• On a stable dose of corticosteroids for at least 6 months.

Exclusion Criteria:

• Previous treatment with the experimental agents BMN-195 (SMT C1100) or PRO053.
• Current or previous treatment with any other experimental treatments within 12 weeks prior to study entry.
• Major surgery within the last 3 months.
• Presence of other clinically significant illness.
• Major change in physical therapy regime within the last 3 months.

Other inclusion and exclusion criteria may apply.

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

United States, Massachusetts
Boston Children's Hospital
Boston, Massachusetts, United States, 02116
France
Institute de Myologie
Paris, France, 75013
Italy
Policlinico Universitario A Gemelli
Rome, Italy, 00168
United Kingdom
Great Ormond Street Hospital for Children NHS Foundation Trust
London, United Kingdom, WC1N 3JH
Newcastle University Hospital
Newcastle, United Kingdom

Sponsors and Collaborators

Sarepta Therapeutics

Institut de Myologie, France

Consultants for Research in Imaging and Spectroscopy

Great Ormond Street Hospital for Children NHS Foundation Trust

Catholic University of the Sacred Heart

Royal Holloway University

SYSNAV

University College, London

University of Newcastle Upon-Tyne

Investigators

Study Director:	Jon Lu, MD PhD	Sarepta Therapeutics
Study Director:	Chris Mix, MD	Sarepta Therapeutics

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Sarepta Therapeutics
ClinicalTrials.gov Identifier:	NCT02310906 History of Changes
Other Study ID Numbers:	4053-101
First Posted:	December 8, 2014
Last Update Posted:	April 18, 2018
Last Verified:	April 2018

Studies a U.S. FDA-regulated Drug Product:		Yes
Studies a U.S. FDA-regulated Device Product:		No

Keywords provided by Sarepta Therapeutics:

Duchenne muscular dystrophy; Exon Skipping; DMD	Exon 53; Ambulatory; Pediatric

Additional relevant MeSH terms:

Muscular Dystrophies; Muscular Dystrophy, Duchenne; Muscular Disorders, Atrophic; Muscular Diseases; Musculoskeletal Diseases	Neuromuscular Diseases; Nervous System Diseases; Genetic Diseases, Inborn; Genetic Diseases, X-Linked